CTXR Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Citius Pharmaceuticals's net margin of -49.65%. Citius Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Citius Pharmaceuticals has a consensus price target of $5.67, signalling upside risk potential of 713.01%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that Citius Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Citius Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Citius Pharmaceuticals's net income of -$9.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Citius Pharmaceuticals's net margin of --. Citius Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.

Citius Pharmaceuticals has a consensus price target of $5.67, signalling upside risk potential of 713.01%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 488.24%. Given that Citius Pharmaceuticals has higher upside potential than Oragenics, analysts believe Citius Pharmaceuticals is more attractive than Oragenics.

Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Citius Pharmaceuticals's net income of -$9.8M is lower than Oragenics's net income of -$3.3M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 1.06x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Citius Pharmaceuticals's net margin of --. Citius Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Citius Pharmaceuticals has a consensus price target of $5.67, signalling upside risk potential of 713.01%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Citius Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Citius Pharmaceuticals.

Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. Citius Pharmaceuticals's net income of -$9.8M is higher than Palatin Technologies's net income of --. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Citius Pharmaceuticals's net margin of --. Citius Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Citius Pharmaceuticals has a consensus price target of $5.67, signalling upside risk potential of 713.01%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 640.74%. Given that Citius Pharmaceuticals has higher upside potential than Theriva Biologics, analysts believe Citius Pharmaceuticals is more attractive than Theriva Biologics.

Citius Pharmaceuticals has a beta of 0.903, which suggesting that the stock is 9.748% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Citius Pharmaceuticals's net income of -$9.8M is lower than Theriva Biologics's net income of -$4.4M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.